In Brief: Cytogen's ProstaScint
Executive Summary
Cytogen's ProstaScint: Imaging agent for prostate cancer will be reviewed at the July 22-24 meeting of FDA's Medical Imaging Drug Advisory Committee, firm says. The ProstaScint NDA was accepted for filing by FDA on March 13...